Natera - NTRA Stock Forecast, Price & News

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.

Natera Stock Performance

Shares of NASDAQ:NTRA opened at $55.17 on Friday. The firm's 50 day simple moving average is $41.80 and its two-hundred day simple moving average is $45.10. The company has a quick ratio of 4.13, a current ratio of 3.58 and a debt-to-equity ratio of 0.63. Natera has a 1-year low of $26.10 and a 1-year high of $129.09.

Natera (NASDAQ:NTRA - Get Rating) last released its earnings results on Thursday, August 4th. The medical research company reported ($1.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.47) by ($0.03). Natera had a negative return on equity of 95.97% and a negative net margin of 79.57%. The business had revenue of $198.20 million for the quarter, compared to analysts' expectations of $193.67 million. During the same quarter in the prior year, the business posted ($1.32) EPS. The business's revenue for the quarter was up 39.6% compared to the same quarter last year. On average, research analysts anticipate that Natera will post -5.73 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have weighed in on NTRA. Stephens initiated coverage on shares of Natera in a report on Monday, April 25th. They issued an "overweight" rating and a $54.00 price objective on the stock. Cowen reduced their price objective on Natera from $110.00 to $100.00 in a research report on Friday, May 6th. Robert W. Baird dropped their target price on Natera from $100.00 to $71.00 in a report on Friday, May 6th. Cowen lowered their price target on Natera from $110.00 to $100.00 in a research report on Friday, May 6th. Finally, The Goldman Sachs Group cut their price objective on shares of Natera from $90.00 to $80.00 and set a "buy" rating on the stock in a research report on Tuesday, April 19th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $93.18.

Insider Activity at Natera

In related news, COO Robert Alan Schueren sold 572 shares of the business's stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $46.26, for a total value of $26,460.72. Following the sale, the chief operating officer now directly owns 572 shares in the company, valued at $26,460.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Natera news, COO Robert Alan Schueren sold 572 shares of Natera stock in a transaction on Friday, July 22nd. The shares were sold at an average price of $46.26, for a total value of $26,460.72. Following the completion of the transaction, the chief operating officer now directly owns 572 shares of the company's stock, valued at approximately $26,460.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Steven Leonard Chapman sold 1,652 shares of the stock in a transaction dated Thursday, June 23rd. The shares were sold at an average price of $35.76, for a total transaction of $59,075.52. Following the completion of the transaction, the chief executive officer now directly owns 64,777 shares of the company's stock, valued at approximately $2,316,425.52. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,966 shares of company stock valued at $550,755. Corporate insiders own 10.27% of the company's stock.